期刊
JOURNAL OF PHARMACEUTICAL SCIENCES
卷 109, 期 11, 页码 3480-3489出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.xphs.2020.08.003
关键词
HIV/AIDS; Drug-combination particle(s); Spray drying; X-ray powder diffraction (XRD); Nanoparticle(s); Powder technology(s); Physical characterization; Drug-excipient interaction(s); Structure
资金
- National Institute of Health (NIH, US) [UM1-AI120176, R61AI149665]
- Unitaid (Switzerland) [2020-39-GLAD]
- NIH [T32 GM007750]
Diverging physicochemical properties of HIV drug combinations are challenging to formulate as a single dosage form. We have found that 2-to-4 hydrophilic and hydrophobic HIV drugs in combination can be stabilized with lipid excipients under a controlled solvent removal process to form a novel pharmaceutical powder distinct from typical amorphous material. This discovery has enabled production of a drug combination nanoparticle (DcNP) powder composed of 3 HIV drugsdwater-insoluble lopinavir (LogP = 4.7) and ritonavir (LogP = 5.6) and water-soluble tenofovir (LogP = -1.6). DcNP powder, exhibiting repeating units of multi-drug-motifs (referred to as MDM), is made by dissolving all constituents in ethanolic solution, followed by controlled solvent removal. The DcNP powder intersperses chemically diverse drug molecules with lipid excipients to form repeating MDM units. The proposed MDM structure is consistent with data collected with X-ray diffraction, differential calorimetry, and time-of-flight secondary ion mass spectrometry. The successful assembly of chemically diverse drugs in MDM structure is likely due to a novel process of making drug combination powders. The method described here has successfully extended to formulating other clinically prescribed antiviral drug combinations, and thus may serve as a platform technology for developing drug combination nanoparticles for treating a wide range of chronic diseases. (C) 2020 Published by Elsevier Inc. on behalf of the American Pharmacists Association.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据